進(jìn)軍國(guó)際市場(chǎng)、積極開(kāi)展國(guó)際合作，是作為全球領(lǐng)先基因治療企業(yè)賽百諾近年來(lái)實(shí)施國(guó)際化戰(zhàn)略的重要內(nèi)容。賽百諾自2008年正式進(jìn)軍國(guó)際市場(chǎng)，一步一個(gè)腳印，國(guó)際市場(chǎng)的拓展取得了可喜成績(jī)。

Enter the international market and extend our world collaboration is a major theme in our globalization for our gene therapy drive. Sibiono has officially entered the global market since 2008. The footsteps are small but impressive on the market share return. 

 2008年，賽百諾與印度及巴基斯坦等十余個(gè)穆斯林國(guó)家進(jìn)行?重組人p53腺病毒注射液?的藥品注冊(cè)和臨床研究工作，簽訂合作協(xié)議，申報(bào)新藥臨床試驗(yàn)，共同開(kāi)發(fā)基因治療市場(chǎng)。

2009年6月，賽百諾與加拿大北美基因診斷與治療有限公司簽署合作協(xié)議，攜手拓展菲律賓及部分東南亞市場(chǎng)。 2009年9月，賽百諾與日本某協(xié)會(huì)合作，為日本腫瘤患者提供“今又生”基因治療服務(wù)。 2010年1月，賽百諾與臺(tái)灣知名醫(yī)藥企業(yè)正式簽訂合作協(xié)議，成功開(kāi)辟臺(tái)灣腫瘤治療市場(chǎng)，并與享有“臺(tái)灣癌癥之母”聲譽(yù)的彭汪嘉康院士強(qiáng)強(qiáng)聯(lián)合，共同開(kāi)展海峽兩岸腫瘤基因治療。 

 2010年3月，賽百諾與巴西簽署合作協(xié)議，攜手申報(bào)“今又生”在巴西的注冊(cè)批件，并共同開(kāi)發(fā)南美基因治療市場(chǎng)。 

 2010年3月，賽百諾與菲律賓簽署合作協(xié)議，共同推動(dòng)基因治療在菲律賓本土生根、開(kāi)花、結(jié)果。 

 2011年3月，賽百諾與馬來(lái)西亞合作伙伴簽署協(xié)議，共同拓展馬來(lái)西亞、新加坡基因治療市場(chǎng)。11月27日，賽百諾在吉隆坡成功舉行了一屆主旨為基因治療的國(guó)際研討會(huì)，并與馬來(lái)西亞投資方合作，就“今又生”在馬來(lái)西亞的代理銷售正式舉行簽約儀式。

 2011年12月，賽百諾與美國(guó)合作伙伴簽署協(xié)議，攜手開(kāi)辟美國(guó)基因治療市場(chǎng)。 2010年3月、2011年3-12月，賽百諾分別在中國(guó)深圳、阿聯(lián)酋迪拜、菲律賓馬尼拉、中國(guó)香港和馬來(lái)西亞吉隆坡舉辦了5次國(guó)際腫瘤基因治療臨床應(yīng)用研討會(huì)會(huì)，來(lái)自瑞士、德國(guó)、加拿大、日本、菲律賓、馬來(lái)西亞、印度尼西亞、新加坡等國(guó)家以及中國(guó)大陸、香港和臺(tái)灣的腫瘤治療專家及基因藥物研究專家近千人次共赴盛會(huì)。

2008 Sibiono signed collaboration agreement with India, Pakistan and more than 10 other Muslim countries for clinical research, drug registration and marketing on ‘rAd-p53, Inj’.2009.6 Sibiono and Canadian N. America Gene Diagnostics & Therapy Co., Ltd. signed an agreement on the joint effort in opening up the Philippino and SE Asian market.2009.9 Sibiono collaborated with a Japanese organization on providing Gendicine® gene therapy tor cancer patients in Japan.

2010.1 Successfully open up the Taiwan cancer treatment market in collaboration with a prominent Taiwan Enterprise . Built up a cross-strait tumor gene therapy with the strong collaboration of Dr WJ Huang, (a member of Chinese Academy of Science, Taiwan, she is also honored as 'mother of Taiwan Cancer Specialty.’

 2010.2 Signed an agreement with Rothschild Group on gene therapy market development in Europe.

2010.3 Signed collaborative agreement with the Philippines on gene therapy for local use and further development.

2010.3 Signed collaborative agreement with Brazil on the joint effect in applying registration and setting up South America gene therapy market.

2011.3 Signed an agreement with the Malaysia collaboration partner for the development of Singapore-Malaysia gene therapy market.

2011.11.27 Successfully sponsored an international symposium on gene therapy at Kuala Lumpur. The Malaysia partner invested and agreed as a Gendicine® representative there.

2011.12 Signed a partnership agreement with an America partner for the market development in gene therapy in the USA.

2010.3 & 2011.3-12 Sibiono held gene therapy clinical application symposia in Shenzhen, Dubai-United Arab Emirates, the Philippines, Hong Kong, Kuala Lumpur. The participants were experts in oncologists and gene therapy drugs totaling near 1000 coming from Switzerland, Germany, Canada, Japan, and S E Asian countries.

徐總在會(huì)場(chǎng)與智利總統(tǒng)親切交流